Skip to main content

Table 6 Safety follow-up

From: Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

 • Physical xamination including oxygen saturation performance status (ECOG) assessment of toxicit concomitant medication

 • Laboratory tests (hematology and chemistry panel) including free T3/T4 and TSH and pregnancy test for women of childbearing potential